apricoxib and Inflammatory-Breast-Neoplasms

apricoxib has been researched along with Inflammatory-Breast-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for apricoxib and Inflammatory-Breast-Neoplasms

Article	Year
Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells. Bioorganic & medicinal chemistry letters, 2011, Oct-15, Volume: 21, Issue:20 An efficient synthesis of apricoxib (CS-706), a selective cyclooxygenase inhibitor, was developed using copper catalyzed homoallylic ketone formation from methyl 4-ethoxybenzoate followed by ozonolysis to an aldehyde, and condensation with sulfanilamide. This method provided multi-gram access of aprocoxib in good yield. Apricoxib exhibited potency equal to celecoxib at inhibition of prostaglandin E2 synthesis in two inflammatory breast cancer cell lines. Topics: Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Inflammatory Breast Neoplasms; Pyrroles; Sulfonamides	2011

Article

Year

Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.

Bioorganic & medicinal chemistry letters, 2011, Oct-15, Volume: 21, Issue:20

An efficient synthesis of apricoxib (CS-706), a selective cyclooxygenase inhibitor, was developed using copper catalyzed homoallylic ketone formation from methyl 4-ethoxybenzoate followed by ozonolysis to an aldehyde, and condensation with sulfanilamide. This method provided multi-gram access of aprocoxib in good yield. Apricoxib exhibited potency equal to celecoxib at inhibition of prostaglandin E2 synthesis in two inflammatory breast cancer cell lines.

Topics: Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Inflammatory Breast Neoplasms; Pyrroles; Sulfonamides

2011